Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

NCT06858410 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Non-Small Cell Lung Cancer

Interventions

DRUG: lorlatinib
OTHER: concurrent/sequential platinum-based chemoradiotherapy

Sponsor

Guangdong Association of Clinical Trials